Seminars in Oncology
Volume 36, Issue 6 , Pages 566-571 , December 2009

Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women

  • Rowan T. Chlebowski

      Affiliations

    • Corresponding Author InformationAddress correspondence to Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2008. Ca Cancer J Clin. 2008;58:71–96
  2. Fu JB, Kau TY, Severson RK, Kalmekerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 2005;127:768–777
  3. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival (Population-based study of 20,561 cases). Ann Oncol. 2002;13:1087–1093
  4. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78:209–215
  5. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006;98:691–699
  6. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann NY Acad Sci. 2009;115:194–205
  7. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005;61:1459–1470
  8. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, et al. Expression, function, and clinical implimentations of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun. 2001;285:340–347
  9. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 2008;14:4417–4426
  10. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res. 2004;10:113–123
  11. Kruezer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol. 2003;32:263–271
  12. Taioli E, Wynder EL. Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 1994;86:869–870
  13. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer. 2005;117:662–666
  14. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss on lung cancer management. Nutrition. 1996;12:S43–S47
  15. Ou SI, Ziogas A, Zell JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): high percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. [abstract 8004] J Clin Oncol. 2008;26(suppl 15):425s
  16. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women. J Clin Oncol. 2007;25:1705–1712
  17. Wakelee HA, Dahlberg SE, Schiller JH, Langer CJ, Sandler AB, Brahmer JR, et al. Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker. [abstract P1–052] J Thorac Oncol. 2007;8(suppl 4):S570
  18. Albain KS, Unger J, Gotay CC, Davies AM, Edelman M, Herbst RS, et al. Toxicity and survival by sex in patients with advanced non-small cell lung cancer carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol. 2007;25(suppl 18):7549
  19. Ross H, Oldham FB, Bandstra B, Sandalie L, Bianco J, Bonomi P, et al. Serum-free estradiol (E2) levels are prognostic in men with chemothearpy-naive advanced non-small cell lung cacner (NSCLC) and performance status (PS). J Clin Oncol Am Soc Clin Oncol Ann Proc. 2007;25(suppl 15):
  20. Baik CS, Strauss GM, Feskanich D. A prospective study of reproductive factors, hormone use, and risk of lung cancer in postmenopausal women. J Clin Oncol. 2009;27:1501
  21. Olsson H, Bladstrom H, Ingvar C. Are smoking-associated cancers prevented or postposned in women using hormone replacement therapy?. Obstet Gynecol. 2003;102:565–570
  22. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 2007;25:5785–5792
  23. Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of case-control study. Oncology. 2007;73:305–310
  24. Rodriguez C, Spencer Feigelson H, Deka A, Patel AV, Jacobs EJ, Thun MJ, et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2008;17:655–660
  25. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsch V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  26. Thatcher N, Chang A, Parikh P, Tan EH, Perng RP, Ganzon D, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer. Lancet. 2005;366:1527–1537
  27. Scagliotti G, Purvish P, von Pawel J, Biesma B, Vansteenkiste J, Mangold C, et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2:S306;(PRS-03)
  28. Ganti AK, Sahmoun AE, Panwalker AW, Tendulkar LL, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006;24:59–63
  29. Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer. 2009;115:4167–4175
  30. Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?. Curr Oncol. 2009;16:21–25
  31. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87:6–12
  32. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109
  33. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(suppl):S18–S77
  34. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13(suppl 9):S5–S17
  35. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  36. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243–3253
  37. Heiss G, Wallace A, Anderson GL, Aragaki A, Beresford SA, Brzysk R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036–1045
  38. Chlebowski RT, Schwartz A, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post hoc analysis of a randomized controlled trial. Lancet. 2009;374:1243–1251
  39. Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. [abstract] Breast Cancer Res Treat. 2006;100(suppl):S2
  40. Clarke CA, Glaser SL, Uratsu SL, Selby JV, Kushi LH, Herrington LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24:49e–50e
  41. Chlebowski RT, Kuller L, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after estrogen plus progestin use in postmenopausal women. N Engl J Med. 2009;360:573–587
  42. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21:6–12
  43. Dobrzycka B, Kinalski M, Piechocka D, Terlikowski SJ. The role of estrogens in angiogenesis in the female reproductive system. Endokrynol Pol. 2009;60:210–214
  44. Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27:5373–5384
  45. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62:2141–2150
  46. Wu CY, Change YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg. 2005;130:979–986
  47. Kawai H, Ishii A, Washiya K, Kon H, Yamaya C, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 2005;11:5084–5089
  48. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27:411–417
  49. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estroegn and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009;15:5359–5368

PII: S0093-7754(09)00190-0

doi: 10.1053/j.seminoncol.2009.10.008

Seminars in Oncology
Volume 36, Issue 6 , Pages 566-571 , December 2009

Article Tools

* Image Usage & Resolution